SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Investigation Report on China's Olmesartan Market, 2009-2018: 1/3 of the World's Adults have High Blood Pressure

[March 14, 2014]

Research and Markets: Investigation Report on China's Olmesartan Market, 2009-2018: 1/3 of the World's Adults have High Blood Pressure

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/8ckb4h/investigation) has announced the addition of the "Investigation Report on China's Olmesartan Market, 2009-2018" report to their offering.

According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.

Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Developed by Sankyo and Forest Laboratories, olmesartan medoxomil was approved to the U.S.A. in April 2002 with the trade name ""Benicar"" and was approved to Europe in October 2002. In July 2006, it was launched in Chinese market. Olmesartan can take effect very soon with low dosage, and it has strong and lasting antihyperensive effect with few adverse reactions, especially dry cough.


Also because of its excellent performance worldwide, many Chinese manufacturers applied to produce the generic drug. However, this behavior caused the noted ""composition patent"" olmesartan patent infringement case in 2006, resulting in the ""Bolar Exception"" in Chinese patent system. Although Beijing Winsunny Pharmaceutical Co., Ltd. won the trial and was approved to produce the genetic drug in 2007, they violates Sankyo's patent every time they produce or sell the product. For Beijing Winsunny Pharmaceutical Co., Ltd., it has won the trial but not the market. Competition pattern of olmesartan medoxomil manufacturers from Menet indicates that olmesartan medoxomil produced by Beijing Winsunny Pharmaceutical Co., Ltd. could not go on the market until patent ZL.97126347.7 expired in 2011. As a result, market share of Beijing Winsunny Pharmaceutical Co., Ltd. is extremely low.

Key Topics Covered:

1 Relevant Concepts of Olmesartan

2 Market Overview of Olmesartan in China, 2009-2013

3 Investigation on Sales Value of Olmesartan in China, 2009-2013

4 Investigation on Market Share of Major Olmesartan Manufacturers in China, 2009-2013

5 Investigation on Market Size of Olmesartan by Dosage Form in China, 2009-2013

6 Reference Price of Olmesartan Produced by Different Enterprises in China Hospital Market

7 Analysis on Major Olmesartan Manufacturers in China, 2009-2014

8 Prospect of China Olmesartan Market, 2014-2018

Companies Mentioned

  • Shanghai Sankyo Pharmaceutical Co., Ltd.
  • Beijing Winsunny Pharmaceutical Co., Ltd.
  • Shanghai Sine Promod Pharmaceutical Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/8ckb4h/investigation


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy